AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

MRS of Glioma Genomics

RecruitingNAAges 18 Years - anyAllInstitut National de la Santé Et de la Recherche …
💬

In plain words

What the trial is, and whether it could suit you

In France, about 5000 new people with a primary malignant brain tumor are diagnosed each year. The most common primary tumors are gliomas, originating from glial cells (astrocytomas and oligodendrogliomas). Low-grade gliomas are mildly aggressive, but they often evolve into a more malignant form. Mutations in the genes encoding isocitrate dehydrogenase (IDH) are found in about 80% of low-grade gliomas and are associated with a favorable prognosis. Remarkably, IDH-mutated gliomas are characterized by a specific cellular metabolism causing the accumulation of D-2-hydroxyglutarate (2HG) in tumor cells. 2HG can be detected in vivo using 1H magnetic resonance spectroscopy (MRS) and is recognized as a unique, noninvasive biomarker of IDH-mutated gliomas. Noninvasive detection of IDH mutations via 2HG MRS represents a crucial step for decision-making and patient care. A subset of IDH-mutated

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria : * Affiliations to a social security scheme (as a beneficiary or a person entitled to benefits) * Obtainig written, informed consent * One of the following two situations * Group 1 : Probable grade II/III/IV glioma, for which excision is scheduled. * Group 2 : Histologically confirmed grade II or III glioma with known IDH1/IDH2 status, which has received no treatment other than surgery and is due to undergo therapy other than surgery. * Presence of measurable tumor residue (\>2 cm in diameter on FLAIR imaging) * Karnofsky Index \> 60 * Effective contraception throughout the study, supplemented by a negative pregnancy test for women of childbearing age. Exclusion Criteria: • Containdications to MRI : Pacemaker or neural stimulators, intraocular or intracerebral metallic foreign bodies, cochlear implant, heart valve or metallic surgical arterial devices that are not MRI ompatible, metallic devices susceptible to concentrating radio-frequency pulses, claustrophobia * Pregnant or breastfeeding women * Regulatory criteria : Pregnant women, women in labor, breastfeeding women ; Failure to sign the consent form or paticipant refusal ; Legal protection measures (guardianship, curatorship, judicial protection) ; Participation in another research study that does not allow for compliance with the exclusion period between the two studies ; Individuals not covered by a health insurance scheme.
💊

What it tests

  • MRI
📍

Where

2 sites
Pitié-Salpetrière Hospital
Paris, France
Hôpital Pitié Salpêtrière, 47 Boulevard de l'Hôpital, 75013 Paris
Paris, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy